Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study will investigate the possibility of using the drug thioridazine (also called
Mellaril) to increase the number of certain types of cells moving from the bone marrow to the
circulation in a group of healthy humans. The types of cells we hope to collect are called
CD34+ progenitor, or stem cells. These cells can be used in the laboratory to better
understand a number of diseases and suggest new strategies for therapy. Perhaps the most
important potential application of human stem cells is the generation of cells and tissues
that could be used for cell-based therapies, as a renewable source of replacement cells and
tissues to treat diseases including Alzheimer's diseases, spinal cord injury, stroke, burns,
heart disease, diabetes, osteoarthritis, and rheumatoid arthritis.